Prostate Cancer - Pipeline Review, H1 2016


#761781

1555pages

Global Markets Direct

$ 2500

In Stock

Prostate Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Prostate Cancer - Pipeline Review, H1 2016, provides an overview of the Prostate Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Prostate Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Prostate Cancer
- The report reviews pipeline therapeutics for Prostate Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Prostate Cancer therapeutics and enlists all their major and minor projects
- The report assesses Prostate Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Prostate Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Prostate Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 13
Prostate Cancer Overview 14
Therapeutics Development 15
Prostate Cancer - Therapeutics under Development by Companies 17
Prostate Cancer - Therapeutics under Investigation by Universities/Institutes 39
Prostate Cancer - Pipeline Products Glance 43
Prostate Cancer - Products under Development by Companies 47
Prostate Cancer - Products under Investigation by Universities/Institutes 77
Prostate Cancer - Companies Involved in Therapeutics Development 83
Prostate Cancer - Therapeutics Assessment 340
Drug Profiles 380
Prostate Cancer - Dormant Projects 1432
Prostate Cancer - Discontinued Products 1477
Prostate Cancer - Product Development Milestones 1486
Appendix 1498

List of Tables
Number of Products under Development for Prostate Cancer, H1 2016 71
Number of Products under Development for Prostate Cancer - Comparative Analysis, H1 2016 72
Number of Products under Development by Companies, H1 2016 73
Number of Products under Development by Companies, H1 2016 (Contd..1) 74
Number of Products under Development by Companies, H1 2016 (Contd..2) 75
Number of Products under Development by Companies, H1 2016 (Contd..3) 76
Number of Products under Development by Companies, H1 2016 (Contd..4) 77
Number of Products under Development by Companies, H1 2016 (Contd..5) 78
Number of Products under Development by Companies, H1 2016 (Contd..6) 79
Number of Products under Development by Companies, H1 2016 (Contd..7) 80
Number of Products under Development by Companies, H1 2016 (Contd..8) 81
Number of Products under Development by Companies, H1 2016 (Contd..9) 82
Number of Products under Development by Companies, H1 2016 (Contd..10) 83
Number of Products under Development by Companies, H1 2016 (Contd..11) 84
Number of Products under Development by Companies, H1 2016 (Contd..12) 85
Number of Products under Development by Companies, H1 2016 (Contd..13) 86
Number of Products under Development by Companies, H1 2016 (Contd..14) 87
Number of Products under Development by Companies, H1 2016 (Contd..15) 88
Number of Products under Development by Companies, H1 2016 (Contd..16) 89
Number of Products under Development by Companies, H1 2016 (Contd..17) 90
Number of Products under Development by Companies, H1 2016 (Contd..18) 91
Number of Products under Development by Companies, H1 2016 (Contd..19) 92
Number of Products under Development by Companies, H1 2016 (Contd..20) 93
Number of Products under Development by Companies, H1 2016 (Contd..21) 94
Number of Products under Investigation by Universities/Institutes, H1 2016 95
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 96
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 97
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 98
Comparative Analysis by Late Stage Development, H1 2016 99
Comparative Analysis by Clinical Stage Development, H1 2016 100
Comparative Analysis by Early Stage Development, H1 2016 101
Comparative Analysis by Unknown Stage Development, H1 2016 102
Products under Development by Companies, H1 2016 103
Products under Development by Companies, H1 2016 (Contd..1) 104
Products under Development by Companies, H1 2016 (Contd..2) 105
Products under Development by Companies, H1 2016 (Contd..3) 106
Products under Development by Companies, H1 2016 (Contd..4) 107
Products under Development by Companies, H1 2016 (Contd..5) 108
Products under Development by Companies, H1 2016 (Contd..6) 109
Products under Development by Companies, H1 2016 (Contd..7) 110
Products under Development by Companies, H1 2016 (Contd..8) 111
Products under Development by Companies, H1 2016 (Contd..9) 112
Products under Development by Companies, H1 2016 (Contd..10) 113
Products under Development by Companies, H1 2016 (Contd..11) 114
Products under Development by Companies, H1 2016 (Contd..12) 115
Products under Development by Companies, H1 2016 (Contd..13) 116
Products under Development by Companies, H1 2016 (Contd..14) 117
Products under Development by Companies, H1 2016 (Contd..15) 118
Products under Development by Companies, H1 2016 (Contd..16) 119
Products under Development by Companies, H1 2016 (Contd..17) 120
Products under Development by Companies, H1 2016 (Contd..18) 121
Products under Development by Companies, H1 2016 (Contd..19) 122
Products under Development by Companies, H1 2016 (Contd..20) 123
Products under Development by Companies, H1 2016 (Contd..21) 124
Products under Development by Companies, H1 2016 (Contd..22) 125
Products under Development by Companies, H1 2016 (Contd..23) 126
Products under Development by Companies, H1 2016 (Contd..24) 127
Products under Development by Companies, H1 2016 (Contd..25) 128
Products under Development by Companies, H1 2016 (Contd..26) 129
Products under Development by Companies, H1 2016 (Contd..27) 130
Products under Development by Companies, H1 2016 (Contd..28) 131
Products under Development by Companies, H1 2016 (Contd..29) 132
Products under Investigation by Universities/Institutes, H1 2016 133
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 134
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 135
Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 136
Products under Investigation by Universities/Institutes, H1 2016 (Contd..4) 137
Products under Investigation by Universities/Institutes, H1 2016 (Contd..5) 138
Prostate Cancer - Pipeline by 4SC AG, H1 2016 139
Prostate Cancer - Pipeline by AB Science SA, H1 2016 140
Prostate Cancer - Pipeline by AbbVie Inc., H1 2016 141
Prostate Cancer - Pipeline by Acino International AG, H1 2016 142
Prostate Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H1 2016 143
Prostate Cancer - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016 144
Prostate Cancer - Pipeline by ADC Therapeutics Sarl, H1 2016 145
Prostate Cancer - Pipeline by Aduro BioTech, Inc., H1 2016 146
Prostate Cancer - Pipeline by Advanced Accelerator Applications S.A., H1 2016 147
Prostate Cancer - Pipeline by Advanced Cancer Therapeutics, H1 2016 148
Prostate Cancer - Pipeline by Advantagene, Inc., H1 2016 149
Prostate Cancer - Pipeline by Advaxis, Inc., H1 2016 150
Prostate Cancer - Pipeline by Aeglea BioTherapeutics, Inc., H1 2016 151
Prostate Cancer - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2016 152
Prostate Cancer - Pipeline by Aeterna Zentaris Inc., H1 2016 153
Prostate Cancer - Pipeline by Aileron Therapeutics, Inc., H1 2016 154
Prostate Cancer - Pipeline by Akshaya Bio Inc., H1 2016 155
Prostate Cancer - Pipeline by Alchemia Limited, H1 2016 156
Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc., H1 2016 157
Prostate Cancer - Pipeline by Almac Discovery Limited, H1 2016 158
Prostate Cancer - Pipeline by Ambrx, Inc., H1 2016 159
Prostate Cancer - Pipeline by American Gene Technologies International Inc., H1 2016 160
Prostate Cancer - Pipeline by Amgen Inc., H1 2016 161
Prostate Cancer - Pipeline by Anavex Life Sciences Corp., H1 2016 162
Prostate Cancer - Pipeline by AndroScience Corporation, H1 2016 163
Prostate Cancer - Pipeline by AnGes MG, Inc., H1 2016 164
Prostate Cancer - Pipeline by AntiCancer, Inc., H1 2016 165
Prostate Cancer - Pipeline by Antigen Express, Inc., H1 2016 166
Prostate Cancer - Pipeline by Antisense Therapeutics Limited, H1 2016 167
Prostate Cancer - Pipeline by Apac Biotech Pvt Ltd, H1 2016 168
Prostate Cancer - Pipeline by Apcure SAS, H1 2016 169
Prostate Cancer - Pipeline by Aphios Corporation, H1 2016 170
Prostate Cancer - Pipeline by APIM Therapeutics AS, H1 2016 171
Prostate Cancer - Pipeline by Aptose Biosciences Inc., H1 2016 172
Prostate Cancer - Pipeline by Armour Therapeutics Inc., H1 2016 173
Prostate Cancer - Pipeline by Arno Therapeutics, Inc., H1 2016 174
Prostate Cancer - Pipeline by ArQule, Inc., H1 2016 175
Prostate Cancer - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016 176
Prostate Cancer - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016 177
Prostate Cancer - Pipeline by Arvinas, Inc., H1 2016 178
Prostate Cancer - Pipeline by Asana BioSciences, LLC, H1 2016 179
Prostate Cancer - Pipeline by Astellas Pharma Inc., H1 2016 180
Prostate Cancer - Pipeline by Asterias Biotherapeutics, Inc., H1 2016 181
Prostate Cancer - Pipeline by AstraZeneca Plc, H1 2016 182
Prostate Cancer - Pipeline by ATLAB Pharma SAS, H1 2016 183
Prostate Cancer - Pipeline by Avipep Pty Ltd, H1 2016 184
Prostate Cancer - Pipeline by Azaya Therapeutics, Inc., H1 2016 185
Prostate Cancer - Pipeline by Bavarian Nordic A/S, H1 2016 186
Prostate Cancer - Pipeline by Baxalta Incorporated, H1 2016 187
Prostate Cancer - Pipeline by Bayer AG, H1 2016 188
Prostate Cancer - Pipeline by Bexion Pharmaceuticals, LLC., H1 2016 189
Prostate Cancer - Pipeline by BHR Pharma, LLC, H1 2016 190
Prostate Cancer - Pipeline by BIND Therapeutics, Inc., H1 2016 191
Prostate Cancer - Pipeline by Bio-Cancer Treatment International Limited, H1 2016 192
Prostate Cancer - Pipeline by Bionature E.A. Ltd., H1 2016 193
Prostate Cancer - Pipeline by Biotest AG, H1 2016 194
Prostate Cancer - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016 195
Prostate Cancer - Pipeline by Blirt S.A., H1 2016 196
Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 197
Prostate Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 198
Prostate Cancer - Pipeline by Camurus AB, H1 2016 199
Prostate Cancer - Pipeline by Can-Fite BioPharma Ltd., H1 2016 200
Prostate Cancer - Pipeline by CEL-SCI Corporation, H1 2016 201
Prostate Cancer - Pipeline by Celgene Corporation, H1 2016 202
Prostate Cancer - Pipeline by CellCentric Ltd, H1 2016 203
Prostate Cancer - Pipeline by Cellceutix Corporation, H1 2016 204
Prostate Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 205
Prostate Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016 206
Prostate Cancer - Pipeline by Celprogen, Inc., H1 2016 207
Prostate Cancer - Pipeline by Chamaeleo Pharma NV, H1 2016 208
Prostate Cancer - Pipeline by CohBar, Inc., H1 2016 209
Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H1 2016 210
Prostate Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2016 211
Prostate Cancer - Pipeline by Corvus Pharmaceuticals, Inc., H1 2016 212
Prostate Cancer - Pipeline by Crescendo Biologics Limited, H1 2016 213
Prostate Cancer - Pipeline by CureVac GmbH, H1 2016 214
Prostate Cancer - Pipeline by CytoVac A/S, H1 2016 215
Prostate Cancer - Pipeline by CZ BioMed Corp, H1 2016 216
Prostate Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016 217
Prostate Cancer - Pipeline by DEKK-TEC, Inc., H1 2016 218
Prostate Cancer - Pipeline by DexTech Medical AB, H1 2016 219
Prostate Cancer - Pipeline by Diffusion Pharmaceuticals Inc., H1 2016 220
Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2016 221
Prostate Cancer - Pipeline by DormaTarg, Inc., H1 2016 222
Prostate Cancer - Pipeline by Eisai Co., Ltd., H1 2016 223
Prostate Cancer - Pipeline by Eli Lilly and Company, H1 2016 224
Prostate Cancer - Pipeline by Emergent BioSolutions Inc., H1 2016 225
Prostate Cancer - Pipeline by Enceladus Pharmaceuticals BV, H1 2016 226
Prostate Cancer - Pipeline by Endo Pharmaceuticals Inc., H1 2016 227
Prostate Cancer - Pipeline by EndoCeutics, Inc., H1 2016 228
Prostate Cancer - Pipeline by Endocyte, Inc., H1 2016 229
Prostate Cancer - Pipeline by EntreChem, S.L., H1 2016 230
Prostate Cancer - Pipeline by Errant Gene Therapeutics, LLC, H1 2016 231
Prostate Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2016 232
Prostate Cancer - Pipeline by ESSA Pharma Inc, H1 2016 233
Prostate Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016 234
Prostate Cancer - Pipeline by Evgen Pharma Plc, H1 2016 235
Prostate Cancer - Pipeline by Exonate Limited, H1 2016 236
Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 237
Prostate Cancer - Pipeline by Ferring International Center S.A., H1 2016 238
Prostate Cancer - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016 239
Prostate Cancer - Pipeline by Fountain Biopharma Inc., H1 2016 240
Prostate Cancer - Pipeline by Fujifilm Corporation, H1 2016 241
Prostate Cancer - Pipeline by G1 Therapeutics, Inc., H1 2016 242
Prostate Cancer - Pipeline by Galectin Therapeutics, Inc., H1 2016 243
Prostate Cancer - Pipeline by Genelux Corporation, H1 2016 244
Prostate Cancer - Pipeline by Genentech, Inc., H1 2016 245
Prostate Cancer - Pipeline by Genmab A/S, H1 2016 246
Prostate Cancer - Pipeline by GenSpera, Inc., H1 2016 247
Prostate Cancer - Pipeline by Gilead Sciences, Inc., H1 2016 248
Prostate Cancer - Pipeline by Glactone Pharma AB, H1 2016 249
Prostate Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 250
Prostate Cancer - Pipeline by GlycoMimetics, Inc., H1 2016 251
Prostate Cancer - Pipeline by GP Pharm, S.A., H1 2016 252
Prostate Cancer - Pipeline by GTx, Inc., H1 2016 253
Prostate Cancer - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016 254
Prostate Cancer - Pipeline by Hybrigenics S.A., H1 2016 255
Prostate Cancer - Pipeline by IC-MedTech, Inc., H1 2016 256
Prostate Cancer - Pipeline by Ideaya Biosciences, Inc., H1 2016 257
Prostate Cancer - Pipeline by IGF Oncology, LLC., H1 2016 258
Prostate Cancer - Pipeline by Ignyta, Inc., H1 2016 259
Prostate Cancer - Pipeline by Immune Pharmaceuticals Inc., H1 2016 260
Prostate Cancer - Pipeline by Immuneed AB, H1 2016 261
Prostate Cancer - Pipeline by Immunocore Limited, H1 2016 262
Prostate Cancer - Pipeline by ImmunoFrontier, Inc., H1 2016 263
Prostate Cancer - Pipeline by Immunomedics, Inc., H1 2016 264
Prostate Cancer - Pipeline by Immupharma Plc, H1 2016 265
Prostate Cancer - Pipeline by Incanthera Ltd., H1 2016 266
Prostate Cancer - Pipeline by Incuron, LLC, H1 2016 267
Prostate Cancer - Pipeline by Innate Immunotherapeutics Ltd, H1 2016 268
Prostate Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 269
Prostate Cancer - Pipeline by Io Therapeutics, Inc., H1 2016 270
Prostate Cancer - Pipeline by Ipsen S.A., H1 2016 271
Prostate Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 272
Prostate Cancer - Pipeline by Johnson & Johnson, H1 2016 273
Prostate Cancer - Pipeline by Jyant Technologies, Inc., H1 2016 274
Prostate Cancer - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 275
Prostate Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 276
Prostate Cancer - Pipeline by Kite Pharma, Inc., H1 2016 277
Prostate Cancer - Pipeline by Komipharm International Co., Ltd., H1 2016 278
Prostate Cancer - Pipeline by Kura Oncology, Inc., H1 2016 279
Prostate Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 280
Prostate Cancer - Pipeline by Lidds AB, H1 2016 281
Prostate Cancer - Pipeline by Luye Pharma Group Ltd., H1 2016 282
Prostate Cancer - Pipeline by MacroGenics, Inc., H1 2016 283
Prostate Cancer - Pipeline by Mallinckrodt Plc, H1 2016 284
Prostate Cancer - Pipeline by MaxiVAX SA, H1 2016 285
Prostate Cancer - Pipeline by Meabco A/S, H1 2016 286
Prostate Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2016 287

List of Figures
Number of Products under Development for Prostate Cancer, H1 2016 71
Number of Products under Development for Prostate Cancer - Comparative Analysis, H1 2016 72
Number of Products under Development by Companies, H1 2016 73
Number of Products under Investigation by Universities/Institutes, H1 2016 95
Comparative Analysis by Late Stage Development, H1 2016 99
Comparative Analysis by Clinical Stage Development, H1 2016 100
Comparative Analysis by Early Stage Products, H1 2016 101
Assessment by Monotherapy Products, H1 2016 396
Assessment by Combination Products, H1 2016 397
Number of Products by Top 10 Targets, H1 2016 398
Number of Products by Stage and Top 10 Targets, H1 2016 398
Number of Products by Top 10 Mechanism of Actions, H1 2016 414
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 414
Number of Products by Top 10 Routes of Administration, H1 2016 432
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 432
Number of Products by Top 10 Molecule Types, H1 2016 434
Number of Products by Stage and Top 10 Molecule Types, H1 2016 434